196 reports of this reaction
1.9% of all VIBEGRON reports
#11 most reported adverse reaction
POLLAKIURIA is the #11 most commonly reported adverse reaction for VIBEGRON, manufactured by Sumitomo Pharma America, Inc.. There are 196 FDA adverse event reports linking VIBEGRON to POLLAKIURIA. This represents approximately 1.9% of all 10,281 adverse event reports for this drug.
Patients taking VIBEGRON who experience pollakiuria should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
POLLAKIURIA is a less commonly reported adverse event for VIBEGRON, but still significant enough to appear in the safety profile.
In addition to pollakiuria, the following adverse reactions have been reported for VIBEGRON:
The following drugs have also been linked to pollakiuria in FDA adverse event reports:
POLLAKIURIA has been reported as an adverse event in 196 FDA reports for VIBEGRON. This does not prove causation, but indicates an association observed in post-market surveillance data.
POLLAKIURIA accounts for approximately 1.9% of all adverse event reports for VIBEGRON, making it a notable side effect.
If you experience pollakiuria while taking VIBEGRON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.